RPTX (Repare Therapeutics, Inc.) רווח למניה בארבעת הרבעונים האחרונים

Repare Therapeutics (RPTX) revenues are based on payments and royalties from Roche for the development of ATR inhibitors, while the lack of its own profitable products creates a dependency on external financing. The EPS (TTM) price action is currently fixed at 14.80. Repare Therapeutics (RPTX) is implementing a synthetic lethality method, which enables the destruction of dangerous tumors by targeting only damaged DNA segments while preserving the integrity of healthy cells.
Repare Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (RPTX)

This indicator is calculated as the percentage change in net earnings per share over the last twelve months relative to the same period last year, measuring the actual efficiency of business capitalization. For Repare Therapeutics (RPTX), which invests in AI screening and CRISPR technologies, the historical year-over-year EPS growth (TTM) reflects the balance between colossal R&D expenditures and the pace of monetizing its technological leadership.